Načítá se...
Activity of Decitabine in Patients with Myelodysplastic Syndrome Previously Treated with Azacitidine
BACKGROUND: Azacitidine and decitabine are two hypomethylating agents approved by the Food and Drug Administration for the treatment of patients with myelodysplastic syndrome (MDS). The efficacy of one agent post failure of the other is unknown. METHODS: Fourteen patients with MDS post azacitidine f...
Uloženo v:
| Hlavní autoři: | , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2008
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3702160/ https://ncbi.nlm.nih.gov/pubmed/18398735 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428190701882146 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|